Our Vision
Elevated Disease Treatment
We envision a future where a diagnosis of cancer, MS or CNS inflammation no longer carries the same fear it does today.
​
At METRUVA Therapeutics, we believe that by understanding how these diseases depend on cellular mobility, we can take away their edge. By targeting the very pathways cells rely on to move, we aim to create treatments that are smarter, more precise, and gentler on the body.
​
Our goal is not only to advance science—but to bring hope. Hope for longer lives. Hope for better quality of life. Hope for families who deserve more time together.​
We are committed to transforming the way disease is treated and giving patients a stronger chance at tomorrow.
The METRUVA Strategic Pillars
1. Metabolic Deciphering
We utilize advanced multi-omics and computational modeling to map the unique "fueling" mechanisms of aggressive diseases. By identifying the specific metabolic pathways that cancer, MS, and CNS inflammation exploit to thrive, we find the vulnerabilities others miss.
​
2. Cellular Movement Arrest
Growth is only half the battle. Our research specifically targets the metabolic shifts—such as oxidative stress adaptation and nutrient flexibility—that allow cells to migrate and colonize organs, causing damage.
​
3. Precision Selectivity
The challenge of metabolic therapy is sparing healthy cells. We design "smart" small molecules and inhibitors that are activated only within the distinct, high-stress metabolic profile of active cellular movement, maximizing therapeutic impact while minimizing systemic toxicity.
​
4. Clinical Urgency
For patients with late-stage or treatment-resistant disease, time is the scarcest resource. We streamline our development pipeline with a focus on high-need indications, ensuring that breakthrough science reaches the bedside with the speed the crisis demands.
Our Mission
At METRUVA Therapeutics, we focus on innovation through our core values:
​
-
M – Metabolism: Exploiting unique biochemical pathways and energy reprogramming to identify and target cellular mobility vulnerabilities.
​
-
E – Elimination: Achieving systemic clearance of actively mobile cells by triggering apoptosis and preventing organ damage.
​
-
T – Targeted: Using "search and destroy" molecular precision to neutralize mobility signatures while sparing healthy tissue.
​
-
R – Responsibility: Upholding the highest ethical standards in data transparency and patient safety throughout the innovative process.
​
-
U – Urgency: Accelerating life-saving research through agile methodologies to move therapies from lab to bedside faster.
​
-
V – Vision: Transforming healthcare from reactive treatment to proactive prevention, aiming for a world without fear of progressive disease.
​
-
A – Accuracy: Leveraging data-driven diagnostics and precise dosing to ensure the right intervention hits the right pathway every time.
​​
​​Through the study of Metabolism, METRUVA pursues the total Elimination of cellular spread via Targeted therapies. Driven by a sense of Responsibility and Urgent need, our Vision is rooted in the Accuracy of our science to redefine the limits of disease treatment.​Together, we strive to transform healthcare.
OUR APPROACH
Cellular Mobility, Reimagined
​
Actively mobile cells reprogram their metabolism to sustain rapid movement, resist therapy, and evade immune detection. METRUVA focuses on identifying and targeting these metabolic dependencies—cutting off the biochemical pathways these cells rely on.
​
By combining deep metabolic biology with translational rigor, we design therapies that:
​
-
Selectively target cancer-specific, MS-specific and CNS inflammation metabolic drivers
​
-
Integrate biomarker-guided development strategies
​
-
Enable precision patient selection
​
-
Deliver differentiated, first-in-class mechanisms of action
Our Platform
Therapeutic Innovations
Our cutting-edge technology focuses on the development of therapies that specifically address the complexities of metabolism in actively mobile cells. By harnessing these unique metabolic pathways, we strive to create safe and effective treatments that demonstrate significant improvements in patient outcomes.
Precision Targeting of Cancer, MS and CNS Inflammation Pathways
​
Our research platform integrates:
​
-
Advanced transporter and metabolic pathway biology​
-
Small-molecule drug discovery​
-
Biomarker-driven clinical strategy​
-
Rigorous preclinical validation
​
This approach allows us to move efficiently from molecular insight to clinical development while maintaining scientific depth and regulatory discipline.
Through rigorous research and pre-clinical work, we are on track for IND filing between late 2027 and 2028. Our commitment to innovation in biotechnology is rooted in enhancing the quality of life for patients battling cancer and metabolic diseases.
Board of Directors
The Team!
